Y-mAbs Platform Overview

Y-mAbs is focused on creating innovations in three key areas: immunotherapies, radioimmunotherapies, and companion diagnostics. Although each platform serves a different purpose, there are synergizing aspects between them:

• Immunotherapies help the body’s own immune system fight cancer by targeting specific pathways in tumor cells
• Radioimmunotherapies build off of the tumor-targeting abilities of immunotherapies to deliver targeted doses of radiation into the tumor
• Companion diagnostics help doctors identify patients who may benefit from specific immunotherapies, or who have a specific risk with a certain treatment

In addition to our diverse scientific platforms, we are also studying the use of MULTI-TAG™ technology to determine if it can enhance the efficacy of certain immunotherapies under development. MULTI-TAG™ is a protein multimerization technology that may help improve tumor-binding capabilities, serum half-life, and T-cell–mediated killing of tumor cells, without inducing an excessive release of cytokines.